IBJNews

Financial pressures stretching Lilly

Back to TopCommentsE-mailPrintBookmark and Share

Eli Lilly and Co. executives are performing their rendition of the 1970s hit “The Rubberband Man.”

But Wall Street isn’t cheering.

In a series of presentations, Lilly executives stretched themselves in four directions at once to convince investors and stock analysts that the company will bend but not break next year, and then snap back stronger than ever in 2015.

However, since Lilly executives started talking Thursday morning, the company’s stock has fallen more than 5 percent to below $48 a share—its lowest since the start of the year.

Lilly brass acknowledged that the Indianapolis-based drugmaker will have a harder-than-expected time meeting a goal of $20 billion in sales next year. That’s because not only will Lilly lose patent protection on its bestseller Cymbalta in December, but it also faces difficulties as the growth of emerging markets has slowed and inflationary policies in Japan have lowered the value of the yen, and therefore of Lilly’s growing sales there.

Chief Financial Officer Derica Rice promised that Lilly would still meet its goals, although it might do so in different ways.

One way Lilly executives have been touting since July is cuts to overhead and research and development expenses. Rice said Lilly’s selling, general and administrative expenses declined $400 million last year and will fall another $300 million to $500 million this year.

“R&D spending will decline in 2014 as the number of Phase 3 assets declines from 13 to eight,” Rice said. Even after 2014, he added, Lilly expects R&D spending to grow slower than revenue, as the company tries to do a better job of advancing only the most promising drugs into the large-scale Phase 3 trials that determine if a drug reaches the market.

But in the next breath, Lilly executives promised they wouldn’t cut R&D too much, for fear of repeating the mistake the company made in 2001, when it lost patent protection on its then-bestseller, Prozac. Lilly cut back on R&D spending then, which contributed to a drought of new drugs the company has suffered since 2005.

“I’m confident we’ll not see another large gap like the one in our rearview mirror,” Rice said.

For the past decade, Lilly executives have been touting the company’s pipeline as the thing that would save the company from a loss of revenue during these lean years. Lilly ramped up the number of drugs in human testing from about 10 a decade ago to roughly 60 now.

But Lilly has suffered a bevy of late-stage failures, leaving it with no drugs with sales potential anywhere close to the $6 billion that Cymbalta will generate this year or the $5 billion a year Zyprexa was producing until its major patents expired in late 2011.

Lilly’s pipeline has certainly had successes—just none that have hit it big in the market. That reality forced Lilly executives Thursday to declare victory based on submissions of drugs to regulators, rather than products on the market.

Lilly has submitted four drugs for market approval this year and analysts expect that some of those, and perhaps all of them, will be approved.

“Today, we’re seeing our strategy bear fruit,” said CEO John Lechleiter.

But that fruit won’t actually bear revenue until well after Cymbalta’s revenue declines precipitously in December when patients switch en masse to cheaper generic versions of the medicine.

That’s why Lilly is talking more than ever about cutting costs. And why investors have cut Lilly’s stock price.

ADVERTISEMENT

  • The blame game
    It is true that Lilly had a one-year 3.8% decline in its R&D spending in 2002. But that spending returned to growth in 2003, and has since risen at an average annual rate of 9.4%. So, blaming that one-time decline 11 years ago for the drought of new drugs the company has suffered since 2005 seems bizarre. Since the onset of that drought, Lilly has spent $33 billion in R&D, plus another $7 billion in acquisitions that have never returned a dime. It is also surprising that this excuse only surfaces now, while for years Lilly has kept boasting about its pipeline and how it would bring to market two drugs per year starting in 2013. Rather than blaming ancient history, Lilly's leadership should look instead at its deficit of competence for having turned the second most innovative company in the industry into one of its least productive ones despite robust R&D spending and an R&D organization that is still regarded as one of the most respected in the industry. If Lilly, as is now feared, must go through another round of layoffs, perhaps it should use the opportunity to put some of its leaders at the top of that list. That would be called accountability.

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. why oh why does this state continue to elect these people....do you wonder how much was graft out of the 3.8 billion?

  2. i too think this is a great idea. I think the vision and need is there as well. But also agree with Wendy that there may be better location in our city to fulfill this vision and help grow the sports of hockey and figure skating in Indy. Also to help further develop other parts of the city that seem often forgotten. Any of the other 6 townships out side of the three northernmost could benefit greatly from a facility and a vision like this. For a vision that sounds philanthropic, the location is appears more about the money. Would really like to see it elsewhere, but still wish the development the best of luck, as we can always use more ice in the city. As for the Ice growth when they return, if schedules can be coordinated with the Fuel, what could be better than to have high level hockey available to go see every weekend of the season? Good luck with the development and the return of the Ice.

  3. How many parking spaces do they have at Ironworks? Will residents have reserved spaces or will they have to troll for a space among the people that are there at Ruth Chris & Sangiovese?

  4. You do not get speeding ticket first time you speed and this is not first time Mr.Page has speed. One act should not define a man and this one act won't. He got off with a slap on the wrist. I agree with judge no person was injured by his actions. The state was robbed of money by paying too much rent for a building and that money could have been used for social services. The Page family maybe "generous" with their money but for most part all of it is dirty money that he obtained for sources that are not on the upright. Page is the kind of lawyer that gives lawyers a bad name. He paid off this judge like he has many other tine and walked away. Does he still have his license. I believe so. Hire him to get you confiscated drug money back. He will. It will cost you.

  5. I remain amazed at the level of expertise of the average Internet Television Executive. Obviously they have all the answers and know the business inside and out.

ADVERTISEMENT